argenx SE (LON:0QW0)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 48.31B +61.9% |
| Revenue (ttm) | 4.01B +70.3% |
| Net Income | 1.29B +33.9% |
| EPS | 19.76 +39.8% |
| Shares Out | n/a |
| PE Ratio | 37.38 |
| Forward PE | 30.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,926 |
| Open | 882.80 |
| Previous Close | 870.30 |
| Day's Range | 875.80 - 902.90 |
| 52-Week Range | 563.60 - 901.80 |
| Beta | -0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
ARGX Maintains Buy Rating -- Price Target Raised to $1,095 by Truist Securities
ARGX Maintains Buy Rating -- Price Target Raised to $1,095 by Truist Securities
ARGX Maintained by RBC Capital -- Price Target Raised to $1100
ARGX Maintained by RBC Capital -- Price Target Raised to $1100
ARGX Maintained by Citizens -- Price Target Raised to $1200
ARGX Maintained by Citizens -- Price Target Raised to $1200
ARGX Maintains by Wedbush -- Price Target Raised to $1150
ARGX Maintains by Wedbush -- Price Target Raised to $1150
ARGX Maintained by HC Wainwright & Co. -- Price Target Raised to $1202
ARGX Maintained by HC Wainwright & Co. -- Price Target Raised to $1202
Argenx price target raised to $1,230 from $1,200 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,230 from $1,200 and keeps an Overweight rating on the shares.
Argenx price target raised to $1,100 from $1,025 at RBC Capital
RBC Capital raised the firm’s price target on Argenx (ARGX) to $1,100 from $1,025 and keeps an Outperform rating on the shares after the company’s positive phase 3 top-line results…
Argenx price target raised to $1,150 from $1,050 at Wedbush
Wedbush raised the firm’s price target on Argenx (ARGX) to $1,150 from $1,050 and keeps an Outperform rating on the shares. The firm notes the company reported positive topline Phase…
Argenx price target raised to $1,100 from $1,037 at Oppenheimer
Oppenheimer raised the firm’s price target on Argenx (ARGX) to $1,100 from $1,037 and keeps an Outperform rating on the shares. The firm notes the company announced positive topline results…
Argenx price target raised to $1,095 from $1,030 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Argenx (ARGX) to $1,095 from $1,030 and keeps a Buy rating on the shares. The firm is boosting its price…
Argenx price target raised to $1,202 from $940 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Argenx (ARGX) to $1,202 from $940 and keeps a Buy rating on the shares. The firm cites the positive readout for the…
Argenx price target raised to $1,200 from $932 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Argenx (ARGX) to $1,200 from $932 and keeps an Outperform rating on the shares. The positive Phase 3 ALKIVIA results…
Argenx price target raised to $1,136 from $1,088 at BofA
BofA raised the firm’s price target on Argenx (ARGX) to $1,136 from $1,088 and keeps a Buy rating on the shares. The company reported positive Phase 3 data from the…
ARGX Looks 31.4% Undervalued on GF Value⢠After Positive Vyvgart Trial Data
ARGX Looks 31.4% Undervalued on GF Value⢠After Positive Vyvgart Trial Data
William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path
William Blair notes that Argenx (ARGX) announced top-line results from the Phase III ALKIVIA trial of Vyvgart in autoimmune myositis, showing a clinically meaningful and statistically significant bene...
ARGX Maintains Overweight Rating, Price Target Raised to $1215 by Piper Sandler
ARGX Maintains Overweight Rating, Price Target Raised to $1215 by Piper Sandler
ARGX Looks 31.4% Undervalued on GF Value⢠as Stock Surges 16.6%
ARGX Looks 31.4% Undervalued on GF Value⢠as Stock Surges 16.6%
ARGX Looks 32.0% Undervalued on GF Valueâ¢
ARGX Looks 32.0% Undervalued on GF Valueâ¢
Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results
Argenx SE stock was up 15.25% on Monday after the company posted results from its ALKIVIA Phase 3 study.
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients wit...
Argenx's Vyvgart Scored Another Win — Why Shares Bolted Higher
Argenx stock surged Monday after its blockbuster autoimmune drug, Vyvgart, showed promise in patients with inflammatory diseases.
argenx SE Transcript: Study update
The ALKIVIA phase III trial of VYVGART in autoimmune myositis met its primary endpoint, showing significant and sustained efficacy in both IMNM and DM, with a favorable safety profile. Regulatory submissions are planned for IMNM, and discussions are ongoing for DM, supporting expansion into rheumatology.